EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib (Q35841043)
scientific article published on January 16, 2012
Language:
(P31) (Q13442814)
(P50) (Q40930518)
(Q6384357)
(Q114291502)
(Q114291501)
(Q89637864)
(Q87726250)
(Q32650026)
(Q125315301)
(Q40092361)
(Q91304324)
(Q56889576)
(P304) 227-235
(P407) (Q1860)
(P433) 3
(P478) 2
(P577) Monday, January 16, 2012
(P921) (Q180614)
(Q71130435)
(P953) https://europepmc.org/articles/pmc3308191?pdf=render
https://europepmc.org/articles/PMC3308191
https://europepmc.org/articles/PMC3308191?pdf=render
https://doi.org/10.1158/2159-8290.cd-11-0341
https://aacrjournals.org/cancerdiscovery/article-pdf/2/3/227/1712589/227.pdf
(P1433) (Q15724440)
(P1476) "EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib" (language: en)
"EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib" (language: en)
(P2093) Patricia Della Pelle
Alexa B. Turke
Erin M. Coffee
Ronald D. Brown
Kenneth E. Hung
Keith T. Flaherty
Jennifer A. Wargo
(P2860) (Q29619648)
(Q42478581)
(Q24597152)
(Q27860458)
(Q39692674)
(Q24298749)
(Q27659493)
(Q37402776)
(Q37393116)
(Q27851457)
(Q27851456)
(Q36360691)
(Q42799629)
(Q27860760)
(Q27851674)
(Q52846071)
(Q27851610)
(Q29616828)
(Q58024790)
other details
description scientific article published on January 16, 2012

External Links